Associated Papers
BRCA1 and BRCA2 carriers with breast, ovarian and prostate cancer demonstrate a different pattern of metastatic disease compared with non-carriers: results from a rapid autopsy programme.
Thorne H et al.
Histopathology, 2023
A high-throughput protocol for mutation scanning of the BRCA1 and BRCA2 genes.
Hondow HL et al.
Bmc Cancer, 2011
21702907 (PubMed )
Supplement: 1471-2407-11-265-S5.XLS › Variants_in_targ._validation
BRCA1 and BRCA2 missense variants of high and low clinical significance influence lymphoblastoid cell line post-irradiation gene expression.
Waddell N et al.
Plos Genetics, 2008
18497862 (PubMed )
Supplement: pgen.1000080.s002.xls › Sheet1
Loss of heterozygosity at the BRCA2 locus detected by multiplex ligation-dependent probe amplification is common in prostate cancers from men with a germline BRCA2 mutation.
Willems AJ et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research, 2008
CpG/CpNpG motifs in the coding region are preferred sites for mutagenesis in the breast cancer susceptibility genes.
Cheung LW et al.
Febs Letters, 2007
Prediction of BRCA1 and BRCA2 mutation status using post-irradiation assays of lymphoblastoid cell lines is compromised by inter-cell-line phenotypic variability.
Lovelock PK et al.
Breast Cancer Research and Treatment, 2007
Sensitivity of BRCA1/2 mutation testing in 466 breast/ovarian cancer families.
Evans DG et al.
Journal of Medical Genetics, 2003
High detection rate for BRCA2 mutations in male breast cancer families from North West England.
Evans DG et al.
Familial Cancer, 2001
Clear cell sarcoma of the kidney in a child with Fanconi anemia.
Trejo Bittar HE et al.
Pediatric and Developmental Pathology : the Official Journal of the Society for Pediatric Pathology and the Paediatric Pathology Society, 0
Select a paper to view details